Related Experiment Video

Updated: Jul 13, 2026

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture
08:32

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture

Published on: March 20, 2026

Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis

Dahlia Lainer-Carr1, Ernest Brahn

  • 1Rheumatology Fellowship Program, UCLA School of Medicine, University of California-Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA.

Nature Clinical Practice. Rheumatology
|August 1, 2007
PubMed

Insights

Angiogenesis inhibition is a promising strategy for treating rheumatoid arthritis by targeting the new blood vessel growth that fuels inflammation and joint damage. Several molecular targets and drugs are being explored for this therapeutic approach.

Area of Science:

  • Rheumatology
  • Oncology
  • Vascular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for rheumatoid arthritis (RA) pathogenesis, driving pannus formation, synovial inflammation, and joint destruction.
  • While extensively studied in cancer, targeting angiogenesis is emerging as a novel therapeutic strategy for inflammatory arthritis like RA.

Purpose of the Study:

  • To explore the potential of angiogenesis inhibition as a therapeutic approach for managing rheumatoid arthritis.
  • To identify key mediators and drug candidates involved in inhibiting angiogenesis for proliferative synovitis.

Main Methods:

  • Review of current research on angiogenesis mediators in rheumatoid arthritis.
  • Investigation of therapeutic targets including vascular endothelial growth factor (VEGF), angiopoietin-TIE system, hypoxia-inducible factor (HIF), and integrin alpha(V)beta(3).
  • Evaluation of drugs such as paclitaxel, 2-methoxyestradiol, and fumagillin analogs for their anti-angiogenic properties.

Main Results:

  • Vascular endothelial growth factor (VEGF) is a primary mediator of angiogenesis in RA, with targeted therapies under development.
  • Other pathways and molecules, including angiopoietins, HIF, and integrins, are also implicated and represent potential therapeutic targets.
  • Several existing and novel compounds demonstrate potential in inhibiting angiogenesis and may be effective against proliferative synovitis.

Conclusions:

  • Angiogenesis inhibition offers a promising therapeutic avenue for rheumatoid arthritis and other inflammatory arthropathies.
  • Targeting specific angiogenic mediators and utilizing anti-angiogenic drugs could effectively manage proliferative synovitis and prevent joint destruction.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...